New early data suggests Precigen Therapeutics’s CAR-T therapy PRGN-3005 could decrease tumour burden in advanced ovarian cancer.
In Phase I data unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, PRGN-3005 decreased tumour burden in 67% of patients with advanced stage platinum resistant ovarian cancer. In addition, there were no reported dose limiting toxicities or neurotoxicities associated with PRGN-3005.
Go deeper with GlobalData
Though the early data is promising, Precigen still has a substantial road ahead to develop PRGN-3005 in ovarian cancer. According to a GlobalData report, ovarian cancer represents a sizeable share of the global clinical trial market, though the field is still grappling with delivering new biomarkers and overcoming racial disparities.
The Phase I/Ib trial of PRGN-3005 (NCT03907527) is now in the dose-finding Phase Ib portion. The Phase I data reported at ASCO entailed 27 patients, and the overall trial has an expected enrolment of 71 patients, as per the trial listing.
Precigen’s CAR-T program
PRGN-3005 is a type of CAR-T therapy, short for chimeric antigen receptor T cell (CAR-T), which entails genetically altering immune cells in a lab that then enter a patient’s body. Though CAR-T therapies have shown promise in indications ranging from leukaemia to glioblastoma, questions are rising over growing challenges in affordability and patient access.
PRGN-3005 specifically targets mucin-16, a protein overexpressed in many forms of ovarian cancer. The cell therapy utilises Precigen’s “UltraCAR-T” platform, which allows for reduced manufacturing time and next-day delivery.
Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
